The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC.

Assess the effect of new serum biomarkers (NTBI and hepcidin) and MRI as indicators of iron overload and their usefulness to monitor iron depletion treatment.

Study the effect of iron overload and iron depletion on intracellular signal transduction, trace metals concentrations in serum and urine and markers of oxidative stress in blood cells and urine.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Patients aged > 18 years with verified low-risk or intermediate-1 risk of myelodysplastic syndrome, with normal cytogenetics and serum-ferritin > 1500 µg/L, or with a transfusion history of =/> red- blood-cell-transfusions.

Exclusion Criteria:

Previous or current venesection

MDS patients eligible for hematopoietic stem cell transplantation

Subject complies with one or more of the following standard exclusion criteria for MRI examination;

If the patient has a pacemaker.

If the patient has a neurostimulator

If the patient has a "aneurismeclips"

If the patient has a foreign object in the eye. If yes, what object.

If the patient has a cochlea-/earimplant.

If the patient has a V/P shunt.

If the patient is claustrophobic.

If the patient has an artificial heart valve.

If the patient has known renal failure, eGFR <30.

If the patient has or will have a liver transplantation.

Other: metal prostheses, metal implant

Presence of inflammation (CRP ≥ 5 mg/L)

Presence of proteinuria or creatinine > 2 x UNL (Upper Normal Limit)

Estimated glomerular filtration rate (GFR) < 60 mL/min

ALAT, ASAT, GT or ALP > 2 x ULN ( Upper Normal Limit)

ALAT > 90 U/L for women, ALAT > 140 U/L for men

ASAT > 70 U/L for women, ASAT > 90 U/L for men

ALP > 210 U/L for women and men

GT > 90 U/L for women ≤ 40 years, GT > 150 U/L for women > 40 years

GT > 160 U/L for men ≤ 40 years, GT > 230 U/L for men > 40 years

Acute or chronic hepatitis

Patients with chronic liver disease Child Pugh Class B and C

Chronic skin disease with rash

Estimated survival < 6 months

Prior or concomitant treatment with other iron chelator therapies within 6 weeks of screening

History of non-compliance to medical regimens, or considered potentially unreliable and/or not cooperative